Skip to main content
OpenTrials
Completed

NCT Number: NCT02925130

Beta2-mimetic and Central Nervous System

Beta2-mimetics such as Salbutamol have been shown to have ergogenic effects. Acute and chronic inhaled or oral doses of Salbutamol have been shown to increase whole body exercise and muscle performances. The underlying mechanisms are however unclear. Some data suggest that Salbutamol may have some effects on the central nervous system which may explain the improved exercise and neuromuscular performances. The present study aims to assess the effects of acite inhaled or oral Salbutamol intake on the neuromuscular system by using neurostimulation techniques and magnetic resonance imaging.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Adrenergic Beta-2 Agonist Effect Albuterol Effect

Age range

18 year–35 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Grenoble University Hospital

Grenoble, 38042, France

About this study

The effects of Salbutamol intake will be assessed by using transcranial magnetic stimulation on one hand and magnetic resonance imaging on the other hand. Maximal voluntary activation and cerebral activation will be measured during motor tasks performed until exhaustion after acute inhaled slabutamol intake, acture oral salbutamol intake or oral placebo intake.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy subjects without respiratory and cordiovascular diseases
  • Male
  • Age between 18 and 35
  • Trained subjects (>6 hours of physical activity per week)
  • Non- or ex-smoker (smoking cessation since at least 1 year)

Exclusion criteria

  • Respiratory, cardiovascular and metabolic diseases
  • Neuromuscular diseases
  • thyrotoxicosis, or diabetes treated with insulin
  • alcoholism
  • MRI contraindication
  • TMS contraindication

Treatment and study plan

Salbutamol

Drug

Acute intake of Albuterol, a beta2-mimetic, either inhaled or oral.

Other names: Albuterol

Placebo

Drug

Acute oral intake of a placebo drug

Other names: Albuterol

Primary outcomes

  1. Maximal voluntary activation

    Time frame: Measured immediatly after treatment intake (within 1 h)

    Measurement performed by using transcranial magnetic stimulation, superimposed on submaximal and maximal quadricep contractions

Secondary outcomes

  1. Cortical activation

    Time frame: Measured immediatly after treatment intake (within 1 h)

    Measurement performed by using magnetic resonance imaging and the intensity of the BOLD signal in response to a motor task.

  2. Exercise endurance

    Time frame: Measured immediatly after treatment intake (within 1 h)

    Time to exhaustion during the exercise muscle test.

Sponsors and collaborators

Lead sponsor

University Hospital, Grenoble

Other

Registry information

Official study title

Beta2-mimetic and Central Nervous System: Effects of Salbutamol on Cortical Excitability and Cerebral Activation

Acronym: BETACTIV

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Oct 5, 2016
Registry last updated
Oct 2, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.